By John Yee, MD, MPH, Vice President, Head of Medical Affairs, US Diabetes
Every year, researchers come together at the American Diabetes Association (ADA) Scientific Sessions, where the latest advances in diabetes prevention, diagnosis and treatment are showcased. This year’s 74th annual Scientific Sessions, held June 13-17 in San Francisco, brought together 18,000 participants from across the U.S. and around the globe, making it the world’s largest diabetes meeting. AstraZeneca presented 43 abstracts summarizing new diabetes research, including a Phase III study on an investigational combination therapy and data that supports the safety and efficacy of approved AstraZeneca products. AstraZeneca’s portfolio of marketed products within three growing classes of non-insulin, anti-diabetes treatments was also highlighted at the meeting.
The data shared at ADA demonstrates AstraZeneca’s dedication to advancing science by continuing to evaluate the efficacy and safety of our approved medications and investigating new treatment options to help patients control the disease. We plan to extend our efforts in the fight against diabetes through our recently expanded portfolio.
In addition to highlighting our portfolio on the Session floor at ADA, our AstraZeneca team proudly participated in the ADA 5K on Sunday morning, June 15. Our employees demonstrated their collective commitment to those living with diabetes by getting moving during the ADA’s Run/Walk.
At AstraZeneca, we are proud to provide meaningful medicines that may help people living with diabetes better manage a complex disease and we are committed to showing our support.
tagged with Diabetes